

[NOT-CA-22-029](#)

National Cancer Institute (NCI) Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors Q & A

General

What is a Notice of Special Interest (NOSI)?

A NOSI is an announcement published in the [National Institutes of Health \(NIH\) Guide for Grants and Contracts](#) that describes a specific topic or area of research that an institute is interested in supporting. The NOSI then directs applicants to one or more active funding opportunity announcements (FOAs) to which they can submit applications on that topic.

What is the due date for applications submitted in response to this NOSI?

Check the “Key Dates” listed in Part 1 of the FOA that you select. Some of the FOAs that you can use to respond to this NOSI use standard NIH due dates, but some do not. Be sure to check the due dates carefully. Applicants are encouraged to apply early to allow adequate time to make any necessary corrections to their application before the due date.

If we are applying to this NOSI, how do we alert NCI staff?

Ideally, prior to your submission you would send an email to Ms. Veronica Chollette at cholletv@nih.gov and Dr. Emily Tonorezos at emily.tonorezos@nih.gov to discuss your proposed research idea. It would be helpful to send a one-page summary including specific aims in advance of the discussion.

I submitted an R01 under a different NOSI. Can I switch to this NOSI and resubmit that application?

Yes, you may submit a revised application to NOT-CA-22-029, even if the original application was submitted under a different NOSI.

For how many years can applications be funded?

Check the “Award Project Period” listed in Section II Award Information in the FOA that you select. Generally, the scope of the proposed project should determine the project period. The maximum project period for R01s and P01s is usually up to 5 years, and the maximum project period for R03 and R21 applications is usually up to 2 years. Be sure, however, to check the project period for your selected FOA.

Will NCI accept applications with multiple Principal Investigators (MPI applications)?

Yes, we encourage MPI applications when such a leadership arrangement aligns with the research aims and goals of the work. MPI applications should include clear, detailed plans for project leadership and management. Before deciding to pursue an MPI application, please carefully review the [MPI policy on the Multiple Principal Investigators Web site](#). It is important to note that for an application to be designated as an Early-Stage Investigator (ESI) application, all PIs on the submission must meet the [NIH definition of ESI](#).

If my application was not funded, may I resubmit it?

In general, yes, resubmissions are allowed. Check the FOA that you are applying for to be sure resubmission applications are permitted. To be considered for this NOSI, your resubmissions must be submitted prior to its end date, which is October 09, 2024.

Does Early-Stage Investigator (ESI) or New Investigator (NI) status apply to applications submitted in

response to the NOSI?

Yes, ESI/NI statuses apply.

For the P01 application, would the NOSI need to apply to all projects, or could there be one project within the P01 that is responsive to the NOSI?

Typically, the overall aims of the P01 must be responsive to the NOSI in order for the P01 to be considered responsive. However, investigators who are considering a P01 submission should reach out to Dr. Tonorezos and Ms. Chollette.

Do paylines vary for submissions in response to NOSI versus parent RO1?

No. Paylines are not adjusted for submissions in response to a NOSI.

Are there restrictions for stage of training or career for these grants? (e.g., can fellows apply?)

If approved by your organization to submit an NIH application, any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is/are invited to work with his/her/their organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Research Design & Population

If I want to test an intervention to increase knowledge of survivorship issues among primary care providers, would that be responsive to this NOSI?

No. Applicants submitting in response to this NOSI must address factors contributing to disparities in survivorship care and outcomes that extend beyond the individual (e.g., survivor, caregiver, clinician) level to include healthcare teams, healthcare systems, community, and policy-level factors.

Are there particular research designs that will or will not be funded by this announcement?

No. However, mixed-method study designs and multilevel interventions are encouraged.

Can you provide an example of an intervention that would be considered multi-level and responsive to this NOSI?

A multilevel intervention occurs at two or more levels—including patient, provider, clinical team, clinic, healthcare institution, and/or community setting—and measures outcomes at three or more levels, while accounting for interactions that occur between and across levels. Investigators with further questions are encouraged to contact Ms. Veronica Chollette at cholletv@nih.gov and Dr. Emily Tonorezos at emily.tonorezos@nih.gov.

Are there specific cancer sites, cancer types, and diseases that NCI is interested in seeing in applications responding to the NOSI?

Applicants submitting in response to this NOSI must focus on survivors of childhood cancers (diagnosed prior to the age of 19) and must include populations commonly experiencing disparities based on race or ethnicity, sex, sexual or gender minority status, insurance status, rural residence, socioeconomic disadvantage, or other demonstrated differences.

Scope and Outcomes

What sorts of studies are encouraged by this NOSI?

Research encouraged through this NOSI includes (but is not limited to) studies that propose to assess factors or practices that result in inequities such as disparities in long-term follow-up care; develop and test novel methods for identifying barriers to survivorship care delivery; evaluate multilevel interventions that promote guideline-concordant survivorship care for childhood cancer survivors; develop and test multilevel interventions to mitigate barriers that contribute to disparities in health outcomes for childhood cancer survivors; and characterize barriers to healthy behaviors for childhood cancer survivor populations that experience health disparities.

Review

How will the applications be reviewed?

Applications are reviewed as per the FOA to which you apply; study sections are not specific to this NOSI. We encourage you to examine the study sections in advance of submitting your application. You also can request a particular study section. Once your application is submitted, ensure that the research questions that you are asking are relevant to your study section and look at the roster of reviewers to see if there is expertise sufficient to review your application. If you feel that an expertise is needed but not represented in the study section to which you're assigned, you can speak to the scientific review officer (SRO) to recommend that expertise.